These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30905318)

  • 1. Combining abiraterone and radiotherapy in metastatic castration-resistant prostate cancer: a review of current evidence.
    Livi L; Detti B; Francolini G; Terziani F; Triggiani L; D'Angelillo RM; Ingrosso G
    Tumori; 2019 Aug; 105(4):277-281. PubMed ID: 30905318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
    Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
    Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone.
    Duarte C; Jimeno A; Kessler ER
    Drugs Today (Barc); 2019 Jan; 55(1):5-15. PubMed ID: 30740608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study.
    Sun Y; Zou Q; Sun Z; Li C; Du C; Chen Z; Shan Y; Huang Y; Jin J; Ye ZQ; Xie L; Lin G; Feng Y; De Porre P; Liu W; Ye D
    Int J Urol; 2016 May; 23(5):404-11. PubMed ID: 26879374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer.
    Arrabal-Martín M; Anglada-Curado F; Cózar-Olmo JM; Soler-Martínez J; Moreno-Jiménez J; Castiñeiras-Fernández J; Ledo-Cepero MJ; Beardo-Villar P; Requena-Tapia MJ; Zuluaga-Gómez A;
    Actas Urol Esp; 2014 Jun; 38(5):327-33. PubMed ID: 24342031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
    Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.
    Giacinti S; Carlini P; Roberto M; Bassanelli M; Strigari L; Pavese F; Aschelter AM; Felici A; Valeriani M; Cognetti F; Marchetti P
    Anticancer Drugs; 2017 Jan; 28(1):110-115. PubMed ID: 27763885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
    Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.
    Smith MR; Rathkopf DE; Mulders PF; Carles J; Van Poppel H; Li J; Kheoh T; Griffin TW; Molina A; Ryan CJ
    J Urol; 2015 Nov; 194(5):1277-84. PubMed ID: 26151676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study on the therapy of castration-resistant prostate cancer : Randomized phase II study of abiraterone acetate with LHRH therapy vs. abiraterone acetate without LHRH therapy in patients with progressive chemotherapy-naive castration-resistant prostate cancer (SPARE) - AP 67/11 of the Association of Urogenital Oncology (AUO)].
    Rexer H
    Urologe A; 2016 May; 55(5):665-7. PubMed ID: 27138632
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
    Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.
    Scott LJ
    Drugs; 2017 Sep; 77(14):1565-1576. PubMed ID: 28819727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial experience with abiraterone acetate in patients with castration-resistant prostate cancer.
    Beardo-Villar P; Ledo-Cepero MJ; Gavira-Moreno R; Soto-Delgado M; Soto-Villalba J; Alvarez-Ossorio JL; Juárez-Soto A
    Actas Urol Esp; 2014 Jun; 38(5):339-45. PubMed ID: 24480574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
    Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer.
    Hahn AW; Gill DM; Nussenzveig RH; Poole A; Farnham J; Cannon-Albright L; Agarwal N
    Clin Genitourin Cancer; 2018 Aug; 16(4):288-292. PubMed ID: 29674118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction.
    Cindolo L; Natoli C; De Nunzio C; De Tursi M; Valeriani M; Giacinti S; Micali S; Rizzo M; Bianchi G; Martorana E; Scarcia M; Ludovico GM; Bove P; Laudisi A; Selvaggio O; Carrieri G; Bada M; Castellan P; Topazio L; Boccasile S; Ditonno P; Chiodini P; Schips L
    Clin Genitourin Cancer; 2017 Oct; 15(5):520-525. PubMed ID: 28478884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy.
    Detti B; D'Angelillo RM; Ingrosso G; Olmetto E; Francolini G; Triggiani L; Bruni A; Borghesi S; Fondelli S; Carfagno T; Santini R; Santoni R; Trodella LE; Livi L
    Anticancer Res; 2017 Jul; 37(7):3717-3722. PubMed ID: 28668865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
    Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
    J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.
    Poon DM; Chan K; Lee SH; Chan TW; Sze H; Lee EK; Lam D; Chan MF
    BMC Urol; 2016 Mar; 16():12. PubMed ID: 27001043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.